Innocan Pharma

Innocan Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Innocan Pharma (INNO.CN) as of Oct 18, 2026 is -1.25 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.80 M USD — a change of -67.21% (higher).

EBITDA

-1.25 MUSD

YoY

-67.21%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Innocan Pharma is 2024 -1.25 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Innocan Pharma was 2023 -3.80 M USD. It decreases by -67.21% higher compared to the previous year.

The Innocan Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-83,000.00 USD
Jan 1, 2018
-1.17 M USD
Jan 1, 2019
-3.00 M USD
Jan 1, 2020
-4.73 M USD
Jan 1, 2021
-7.48 M USD
Jan 1, 2022
-6.27 M USD
Jan 1, 2023
-3.80 M USD
Jan 1, 2024
-1.25 M USD
The Innocan Pharma EBITDA history
YEAREBITDAYoY
-1.25 MUSD-67.21%
-3.80 MUSD-39.31%
-6.27 MUSD-16.23%
-7.48 MUSD+58.31%
-4.73 MUSD+57.45%
-3.00 MUSD+157.38%
-1.17 MUSD+1,304.82%
-83,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Innocan Pharma Stock analysis

What does Innocan Pharma do? InnoCan Pharma Corp, based in Herzliya, Israel, operates in the Health Care sector as a pharmaceutical technology company. The company focuses on three segments: developing and distributing its own OTC pharmaceutical products, conducting R&D for non-pharmaceutical products for third parties, and creating hydrogels with liposomes for licensing to pharmaceutical corporations. It is also advancing a new OTC topical treatment line and a platform for targeted cannabinoid delivery via injection. Innocan Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innocan Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Innocan Pharma is -1.25 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Innocan Pharma changed from -3.80 M USD to -1.25 M USD, representing a -67.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Innocan Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Innocan Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Innocan Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Innocan Pharma